BioRestorative Therapies, Inc. BRTX 深 沪
等待开盘 10-15 09:30:00 美东时间
1.50
-0.090
-5.66%
华盛通- 最 高1.56
- 今 开1.50
- 成交量 1.84万股
- 最 低 1.4201
- 昨 收 1.59
- 总市值 207.17万
- 52周最高 34.00
- 市盈率 静 --
- 换手率 1.33%
- 52周最低 1.4201
- 委 比 57.72%
- 总股本 138.11万
- 历史最高 178.00
- 量 比 0.47
- 振 幅 8.80%
- 历史最低 1.4201
- 每 手 1
- 风险率 9.69%
个股概要
财务分析
公司资料
相关新闻
分红派息
- 分时图
- 日k
- 周k
- 月k
相关新闻
更多Maxim Group Downgrades BioRestorative Therapies to Hold
Maxim Group analyst Michael Okunewitch downgrades BioRestorative Therapies (NASDAQ:BRTX) from Buy to Hold.
10-07 04:03
Why Snowflake Shares Are Trading Higher By Over 24%; Here Are 20 Stocks Moving Premarket
Shares of Snowflake Inc (NYSE:SNOW) rose sharply in pre-market trading after the company posted upbeat financial results for the second quarter. Snowflake reported second-quarter revenue of $1.55 billion, beating analyst estimates of $1.48 billion, according to Benzinga Pro. The AI data cloud compan...
09-03 16:43
BioRestorative Therapies Announces 1-For-20 Reverse Stock Split
BioRestorative Therapies, Inc. (NASDAQ:BRTX) ("BioRestorative" or the "Company"), a late-stage clinical regenerative medicine company, today announced that the Company’s Board of Directors approved a 1-for-20 reverse stock split (the "Reverse Stock Split") of the Company’s common stock (the "Common ...
09-03 05:29
BioRestorative Therapies Completes Production For Its BRTX-100 Phase 2 Clinical Study To Support Current Clinical Development To Treat Chronic Lumbar Disc Disease
BioRestorative Therapies, Inc. ("BioRestorative," "BRTX," or the "Company") (NASDAQ:BRTX), a late-stage clinical regenerative medicine company focused on stem cell-based therapies and products, today announced the successful completion of manufacturing for its BRTX-100 Phase 2 clinical trial, markin...
06-25 20:17
BioRestorative Therapies Doses Last Participant In Its Phase 2 Clinical Study Of BRTX-100 To Treat Chronic Lumbar Disc Disease
BioRestorative Therapies, Inc. ("BioRestorative," "BRTX," or the "Company") (NASDAQ:BRTX), a late-stage clinical regenerative medicine company focused on stem cell-based therapies and products, today announced that the
05-26 23:03
12 Health Care Stocks Moving In Tuesday's After-Market Session
Gainers Co-Diagnostics (NASDAQ:CODX) shares rose 20.8% to $2.38 during Tuesday...
05-20 05:06
BioRestorative Therapies Reports 52% Of Phase 2 Patients Achieve At Least 50% Pain And Function Improvement At 52 Weeks With No Dose-Limiting Toxicity In ISCT 2026 Update
Oral presentation at ISCT 2026 included larger 52-week follow-up cohort, with 52% of evaluable patients achieving at least 50% improvement in both VAS pain and ODI function measures and no dose-limiting toxicity safety
05-08 00:09
BioRestorative Therapies To Reveal New Data At ISCT 2026 Highlighting Its Ongoing Phase 2 Clinical Trial in Chronic Lumbar Disease And Its BioCosmeceutical Platform
BioRestorative Therapies, Inc. ("BioRestorative," "BRTX," or the "Company") (NASDAQ:BRTX), a late-stage clinical regenerative medicine company focused on stem cell-based therapies and products, today announces that it
04-30 22:39
BioRestorative Announces Blinded Data From Phase 2 Clinical Trial Evaluating Hypoxic-Cultured Mesenchymal Stem Cells For Treatment Of Chronic Lumbar Disc Disease; Data Shows 50% Or More Of Patients Reporting >50% Improvement In Key Pain And Function Scales
BioRestorative Therapies, Inc. ("BioRestorative," "BRTX," or the "Company") (NASDAQ:BRTX), a late-stage clinical regenerative medicine company focused on stem cell-based therapies and products, today announced blinded
03-30 20:05
BioRestorative Therapies Q4 EPS $(0.32) Misses $(0.30) Estimate, Sales $19.600K Miss $520.000K Estimate
BioRestorative Therapies (NASDAQ:BRTX) reported quarterly losses of $(0.32) per share which missed the analyst consensus estimate of $(0.30) by 4.92 percent. This is a 60 percent decrease over losses of $(0.20) per share
03-27 05:49
